Aardvark Therapeutics, Inc. - Common Stock (AARD)

PHILADELPHIA, Nov. 02, 2026 (GLOBE NEWSWIRE) --

PHILADELPHIA, Oct. 30, 2026 (GLOBE NEWSWIRE) --

PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) --

SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101.

Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume

PHILADELPHIA , Oct. 21, 2026 (GLOBE NEWSWIRE) --

PHILADELPHIA, Oct. 20, 2026 (GLOBE NEWSWIRE) --

PHILADELPHIA, Oct. 19, 2026 (GLOBE NEWSWIRE) --

PHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) --

PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and certain officers and directors.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-cv-04643, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 13, 2025 (the “IPO” or “Offering”); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”).  Plaintiff pursues claims against the Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.

A securities class action alleges Aardvark Therapeutics' SEC filings warned about clinical risk in generic terms while describing ARD-101 as "99% restricted to the gut" with "no serious adverse events" and "no renal or hepatic safety limitations" — language the complaint contends did not disclose the specific cardiac safety issues that later drew a full FDA clinical hold.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Pension funds, asset managers, and other fiduciaries holding Aardvark Therapeutics, Inc. (NASDAQ: AARD) positions acquired in or after the February 2025 IPO may wish to evaluate lead plaintiff options, as a securities class action alleges the Company misrepresented the safety and tolerability of ARD-101 before a Phase 3 trial pause and a full FDA clinical hold.

LOS ANGELES, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

PHILADELPHIA, Oct. 10, 2026 (GLOBE NEWSWIRE) --

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aardvark (AARD) To Contact Him Directly To Discuss Their Options